Richard Law
Stock Analyst at Goldman Sachs
(2.63)
# 1,873
Out of 5,173 analysts
77
Total ratings
36.11%
Success rate
8.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals | Maintains: Buy | $38 → $27 | $13.97 | +93.27% | 8 | Mar 18, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Neutral | $65 → $95 | $98.54 | -3.59% | 1 | Mar 3, 2026 | |
| RCKT Rocket Pharmaceuticals | Maintains: Sell | $2 → $3 | $4.34 | -30.88% | 4 | Mar 2, 2026 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $30 → $34 | $31.80 | +6.92% | 4 | Mar 2, 2026 | |
| MLTX MoonLake Immunotherapeutics | Downgrades: Sell | $8 → $10 | $16.87 | -40.72% | 5 | Jan 15, 2026 | |
| RCUS Arcus Biosciences | Upgrades: Buy | $16 → $28 | $21.41 | +30.78% | 1 | Jan 13, 2026 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $67 | $34.71 | +93.03% | 2 | Jan 12, 2026 | |
| NUVL Nuvalent | Maintains: Buy | $120 → $135 | $96.43 | +40.00% | 1 | Nov 18, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Neutral | $19 → $29 | $22.29 | +30.10% | 2 | Oct 30, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $32 → $52 | $23.65 | +119.87% | 7 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $30 | $27.62 | +8.62% | 4 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $4 → $3 | $5.78 | -48.05% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $30 | $32.55 | -7.83% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 | $15.03 | -26.81% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $25.17 | +86.73% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $46.88 | +34.39% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $76.96 | -51.92% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $13.11 | +479.71% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $2.40 | +483.33% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $10.32 | +491.09% | 4 | May 8, 2023 |
Olema Pharmaceuticals
Mar 18, 2026
Maintains: Buy
Price Target: $38 → $27
Current: $13.97
Upside: +93.27%
Protagonist Therapeutics
Mar 3, 2026
Maintains: Neutral
Price Target: $65 → $95
Current: $98.54
Upside: -3.59%
Rocket Pharmaceuticals
Mar 2, 2026
Maintains: Sell
Price Target: $2 → $3
Current: $4.34
Upside: -30.88%
Celldex Therapeutics
Mar 2, 2026
Maintains: Neutral
Price Target: $30 → $34
Current: $31.80
Upside: +6.92%
MoonLake Immunotherapeutics
Jan 15, 2026
Downgrades: Sell
Price Target: $8 → $10
Current: $16.87
Upside: -40.72%
Arcus Biosciences
Jan 13, 2026
Upgrades: Buy
Price Target: $16 → $28
Current: $21.41
Upside: +30.78%
Crinetics Pharmaceuticals
Jan 12, 2026
Upgrades: Buy
Price Target: $67
Current: $34.71
Upside: +93.03%
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $120 → $135
Current: $96.43
Upside: +40.00%
Arcutis Biotherapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $19 → $29
Current: $22.29
Upside: +30.10%
Mineralys Therapeutics
Sep 9, 2025
Maintains: Buy
Price Target: $32 → $52
Current: $23.65
Upside: +119.87%
Aug 7, 2025
Maintains: Buy
Price Target: $27 → $30
Current: $27.62
Upside: +8.62%
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $5.78
Upside: -48.05%
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $32.55
Upside: -7.83%
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $15.03
Upside: -26.81%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $25.17
Upside: +86.73%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $46.88
Upside: +34.39%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $76.96
Upside: -51.92%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $13.11
Upside: +479.71%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $2.40
Upside: +483.33%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $10.32
Upside: +491.09%